GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
30.22
-0.92 (-2.95%)
At close: Feb 13, 2026

HKG:2595 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023
Period Ending
Jun '25 Dec '24 Dec '23
193.45104.773.73
Revenue Growth (YoY)
-42.00%-
Cost of Revenue
37.0220.10.68
Gross Profit
156.4384.6173.05
Selling, General & Admin
76.5258.0849.95
Research & Development
239.76303.32308.94
Operating Expenses
316.28361.41358.88
Operating Income
-159.85-276.8-285.83
Interest Expense
-6.39-6.12-1.49
Interest & Investment Income
16.3517.2310.77
Currency Exchange Gain (Loss)
1.733.543.82
Other Non Operating Income (Expenses)
6.47-4.9721.75
EBT Excluding Unusual Items
-141.7-267.12-250.98
Gain (Loss) on Sale of Investments
0.110.43.59
Gain (Loss) on Sale of Assets
-0.01-0.01-0.14
Other Unusual Items
-785.33-410.91-260.79
Pretax Income
-926.92-677.64-508.32
Net Income
-926.94-677.64-508.32
Net Income to Common
-926.94-677.64-508.32
Shares Outstanding (Basic)
262622
Shares Outstanding (Diluted)
262622
Shares Change (YoY)
-17.40%-
EPS (Basic)
-35.22-26.20-23.08
EPS (Diluted)
-35.22-26.20-23.08
Free Cash Flow
-94.18-206.64-202.65
Free Cash Flow Per Share
-3.58-7.99-9.20
Gross Margin
80.86%80.81%99.07%
Operating Margin
-82.64%-264.36%-387.66%
Profit Margin
-479.17%-647.20%-689.40%
Free Cash Flow Margin
-48.68%-197.35%-274.85%
EBITDA
-152.82-268.3-274.33
EBITDA Margin
-79.00%-256.25%-
D&A For EBITDA
7.038.511.5
EBIT
-159.85-276.8-285.83
EBIT Margin
-82.63%-264.36%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.